Enovis Corporation (NYSE:ENOV) Given Average Recommendation of “Moderate Buy” by Brokerages

Enovis Corporation (NYSE:ENOV) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $41.2857.

A number of research analysts have recently commented on the company. UBS Group reissued a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Canaccord Genuity Group reduced their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Wells Fargo & Company decreased their price objective on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a report on Friday, August 7th.

Enovis Price Performance

Shares of NYSE:ENOV opened at $24.79 on Tuesday. The firm’s 50 day moving average is $24.91 and its two-hundred day moving average is $24.05. The firm has a market capitalization of $1.43 billion, a P/E ratio of -1.29 and a beta of 1.34. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis has a 52 week low of $19.14 and a 52 week high of $34.28.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period in the previous year, the firm posted $0.79 earnings per share. The business’s revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis will post 3.12 earnings per share for the current year.

Insider Activity

In other news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enovis

Several hedge funds and other institutional investors have recently bought and sold shares of ENOV. Arax Advisory Partners acquired a new stake in Enovis in the 4th quarter valued at about $29,000. Allworth Financial LP acquired a new position in shares of Enovis in the 2nd quarter worth approximately $36,000. EverSource Wealth Advisors LLC grew its stake in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Enovis in the 2nd quarter worth approximately $48,000. Finally, Danske Bank A S acquired a new stake in Enovis during the third quarter valued at approximately $64,000. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.